Recall skin tests. This tests immune responsiveness to challenge with 
antigens which virtually all individuals have been exposed to previously: 
Candida albicans, streptokinase/streptodornase, and mumps. 
9.2 Immune response directed at autologous tumor cells. The preclinical 
work suggests that the intraperitoneal vaccine procedure will achieve a 
systemic immunity. We will evaluate this aspect of the response in two 
ways. 
Autologous tumor cell skin tests. Prior to treatment and subsequent to 
each vaccine administration, the patients will be challenged with 10 6 
radiated autologous tumor cells (if available) given as an intradermal 
injection. The tissue will have been obtained from the patient’s initial 
surgical resection. We have previously used this skin testing in studies 
with renal carcinoma. The procedure is described in Appendix A. 
Lymphocyte cytotoxic assay. Using the patient’s lymphocytes as effector 
cells and autologous tumor cells as targets, we will determine if a 
population of cytotoxic lymphocytes is produced by the immunizing 
procedure. The methods are described in Appendix C. 
9.3 Immune responses directed at MHC antigens on the allogeneic ovarian 
tumor cells of the vaccine. It may be difficult to detect immune responses 
directed at autologous tumor antigens (sec. 9.2). However, responses to 
the MHC antigens should definitely occur and be measurable. Although 
this is a Phase I study and the patient numbers are necessarily sm.„i, we 
will be observing for T cell and B cell responses and comparing low 
levels of vaccine cell dose with higher levels. 
Cytotoxic assays. This will be performed concurrently with the 
autologous tumor cell assay but t e target cell line will be the PA-1 
used in the vaccine. 
Anti-HLA antibodies. The HLA antigens exposed on the SK OV-3 line 
will be determined through the tissue typing laboratory. Serum 
specimens will be serially obtained from each patient to determine an 
antibody titer directed at the HLA molecule. 
9.4 The CA 125 marker level will be determined prior to beginning therapy 
and prior to each vaccine cycle. 
[598] 
Recombinant DNA Research, Volume 15 
